Genitourinary Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genitourinary deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of genitourinary deals from 2016 to 2023.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of genitourinary dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in genitourinary dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the genitourinary field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in genitourinary dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of genitourinary deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of genitourinary deals listed by theraeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in genitourinary deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Genitourinary Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Fully revised and updated, the report provides details of genitourinary deals from 2016 to 2023.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of genitourinary dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in genitourinary dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the genitourinary field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in genitourinary dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of genitourinary deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of genitourinary deals listed by theraeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in genitourinary deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Genitourinary Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse genitourinary collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report scope
Genitourinary Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of genitourinary trends and structure of deals entered into by leading biopharma companies worldwide.Genitourinary Collaboration and Licensing Deals includes:
- Trends in genitourinary dealmaking in the biopharma industry
- Overview of collaboration and licensing deal structure
- Directory of genitourinary deal records covering pharmaceutical and biotechnology
- The leading genitourinary deals by value
- Most active genitourinary licensing dealmakers
In Genitourinary Collaboration and Licensing Deals, the available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Genitourinary Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in genitourinary dealmaking
Chapter 3 - Financial deal terms for genitourinary partnering
Chapter 4 - Leading genitourinary deals and dealmakers
Chapter 5 - Genitourinary contract document directory
Chapter 6 - Genitourinary dealmaking by therapeutic target
Deal Directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio
- 4D Science
- 180 Medical
- A1M Pharma
- AbbeyMoor Medical
- Abbott Laboratories
- Abbvie
- Acer Therapeutics
- Acerus
- Aceso Life Science
- Aceto Corporation
- Acino Pharma
- ACIST Medical Systems
- Acon Labs
- Actient Pharmaceuticals
- Action Pharma
- ActivStyle
- Acurx Pharmaceuticals
- AdaptHealth
- Aduro BioTech
- Advanced Uro-Solutions
- Advanz Pharma
- Advicenne
- AEterna Zentaris
- Aethlon Medical
- Aetna
- Affymax
- AirStrip Technologies
- Akcea Therapeutics
- Akebia Therapeutics
- AKESOgen
- Alavita Pharmaceuticals
- AlCana Technologies
- Alcavis HDC
- Alere Health
- Algernon Pharmaceuticals
- Alio Medical
- AliveCor
- Alivio Therapeutics
- Allecra Therapeutics
- Allegis Pharmaceuticals
- Allena Pharmaceuticals
- Allergan
- Allium Medical Solutions
- Alnylam Pharmaceuticals
- Altasciences
- Altavant Sciences
- Althea Technologies
- AltheRx
- AM-Pharma
- Amag Pharmaceuticals
- Ambu
- American Access Care
- American Diabetes Association
- American Lung Association
- American Medical Systems
- American Renal Associates
- American Urological Association
- Amerigen Pharmaceuticals
- Amerinet
- AmerisourceBergen
- Amgen
- AmorChem
- Ampio Pharmaceuticals
- Amplity Health
- Anakuria Therapeutics
- ANDROMEDA Medizinische Systems
- Angelini Pharma
- Angion Biomedica
- Angiotech Pharmaceuticals
- ANI Pharmaceuticals
- Antares Pharma
- Anteris Bio
- Anthem
- Anthem Bluecross
- Anthera Pharmaceuticals
- AorTech
- Apax Partners
- Apellis Pharmaceuticals
- Apocell
- Apollo Hospitals Group
- Applied Medical
- Aquestive Therapeutics
- Aquinox Pharmaceuticals
- Arch Biopartners
- Archimedes Pharma
- Ardelyx
- Arena Pharmaceuticals
- Argon Medical Devices
- Argutus Medical
- Arizona State University
- Arkray USA
- Arrevus
- Arriani Pharmaceuticals
- Asahi Kasei
- Ascend Clinical
- Ascend Therapeutics
- ASC Therapeutics
- ASD Speciality Healthcare
- Asia Renal Care
- ASKA Pharmaceuticals
- Aspect Biosystems
- Assembly Biosciences
- Astellas Pharma
- Astellas Pharma US
- AstraZeneca
- Astute Medical
- Atara Biotherapeutics
- Atlantic Dialysis Management Services
- Aurinia Pharmaceuticals
- Auven Therapeutics
- Auxilium Pharmaceuticals
- Avanti Specialty Pharmacy Management
- Avenu Medical
- AWAK Technologies
- Axonics Modulation Technologies
- Ayogo Health
- Aytu BioPharma
- Aziyo Biologics
- Balboa Nephrology Medical Group
- Bausch & Lomb
- Baxter International
- Baylor Health Care System
- B Braun
- Beacon Discovery
- Beckman Coulter
- Becton Dickinson
- Beijing King Health
- Beijing Leadman Biochemistry
- Bellco Health Care
- Bellus Health
- BenevolentAI
- Beth Israel Deaconess Medical Center
- Biim Ultrasound
- Bio-Techne
- BIOASTER
- BioCad Holding
- Biocon
- BioDerm
- BioLink Life Sciences
- Biomedical Advanced Research and Development Authority
- Biomerica
- bioMerieux
- BioPorto
- BioSerenity
- Biostar Pharmaceuticals
- BioVectra
- BK Medical
- Blackstone
- Bladder Health Network
- Blue Cross Blue Shield Association
- Boehringer Ingelheim
- Boston Scientific
- Bridge Medicines
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
